Adaptimmune

Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy.

paul.newey — Wed, 16 Jan 2013 13:00:58 +0000

NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1^c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune’s clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).

Click on here to download full Press Release

Press Articles from the Life Technologies Press release

paul.newey — Wed, 09 Jan 2013 09:30:51 +0000

Pharma Live on 7th January – http://www.pharmalive.com/News/Index.cfm?articleid=873143
BioPortfolio on 7th January – http://www.bioportfolio.com/news/article/1283578/Adaptimmune-Announces-Exclusive-License-With-Life-Technologies-Corporation-On-Proprietary-Manufacturing-Process.html
BioSpace on 7th January – http://www.biospace.com/News/adaptimmune-ltd-announces-exclusive-license-with/284065
Fierce Biotech on 8th January - http://www.fiercebiotechresearch.com/press-releases/adaptimmune-announces-exclusive-license-life-technologies-corporation-propr
Pharmaceutical Business Review on 8th January – http://contractservices.pharmaceutical-business-review.com/news/adaptimmune-gains-licensing-rights-to-life-tech-antibody-coated-magnetic-beads-080113
Technology Networks on 7th January - http://www.technologynetworks.com/news.aspx?id=147525
Financial Times Weekend magazine on 11th January – http://www.ft.com/cms/s/2/a40f14fa-59fa-11e2-b728-00144feab49a.html#axzz2HlgR45m6

Exclusive License with Life Technologies Corporation on Proprietary Manufacturing Process for T Cell Therapy

paul.newey — Mon, 07 Jan 2013 09:06:23 +0000

Adaptimmune announces that it has secured an exclusive commercial license from Life Technologies Corporation for its intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR). Life’s Dynabeads® CD3/CD28 CTS™ are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy.

Click on here to download full Press Release

Press Articles from the ASH Press release

paul.newey — Tue, 18 Dec 2012 12:43:37 +0000

New Scientist online – with video – http://www.newscientist.com/article/dn22613-soupedup-immune-cells-force-leukaemia-into-remission.html
BioSpace on 11 December – http://www.biospace.com/News/adaptimmune-ltd-announces-preliminary-results-from/282010
Drug Discovery & Development on 12 December – http://www.dddmag.com/news/2012/12/adaptimmune-releases-myeloma-study-data
BioPortfolio on 11 December – http://www.bioportfolio.com/news/article/1258787/Adaptimmune-Announces-Preliminary-Results-From-An-Early-Phase-Trial-Of-Gene-Engineered.html
Clinica on 13 December – http://www.clinicaspace.com/News/adaptimmune-ltd-announces-preliminary-results-from/282279
Biotechnology Europe on 10 December – http://www.biotechnology-europe.com/UK.html
Pharma Live on 10 December – http://www.pharmalive.com/News/index.cfm?articleid=870546&categoryid=40#
Technology Networks on 11 December – http://www.technologynetworks.com/RNAi/index.aspx
Drugs.com Clinical Trials on 10 December – http://www.drugs.com/clinical_trials/adaptimmune-announces-preliminary-results-early-phase-trial-gene-engineered-t-cells-targeting-14848.html
OBN on 10 December – http://www.obn.org.uk/obn_/news_item.php?r=PS3OWI518671
Biocentury on 17 December – http://www.biocentury.com/weekinreview/clinicalresults/2012-12-17/enhanced-tcr-therapy-for-mm-preliminary-phase-iii-data-303336

Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

paul.newey — Mon, 10 Dec 2012 22:30:11 +0000

(Atlanta, GA and Oxford, UK) 10 December, 2012. Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study presented today in three separate sessions at the annual meeting of the American Society of Hematology (ASH).

Please click here for full Press Release

Investigators to Present Preliminary Adaptimmune’s Findings for Gene Engineered T Cells in Myeloma

paul.newey — Fri, 16 Nov 2012 08:00:59 +0000

Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study will be presenting the data on December 10^th at the annual meeting of the American Society of Hematology (ASH).

Please click here for full Press Release

James Noble MA FCA, Chief Executive Officer

liam.dempsey — Mon, 06 Aug 2012 14:33:49 +0000

See profile on Directors’ page

Bent Jakobsen PhD, Chief Scientific Officer

liam.dempsey — Sun, 05 Aug 2012 15:39:44 +0000

See profile on Directors’ page

Helen Tayton-Martin PhD MBA, Chief Operating Officer

liam.dempsey — Sat, 04 Aug 2012 15:40:26 +0000

See profile on Directors’ page

Gwen Binder-Scholl PhD, Executive Vice President

liam.dempsey — Fri, 03 Aug 2012 15:41:04 +0000

Gwendolyn Binder-Scholl is responsible for driving all aspects of Adaptimmune LLC including its ongoing clinical trials in HIV and cancer and strategic development planning. She is a biochemistry and molecular biology graduate of Wells College, New York with a PhD in Cellular and Molecular Medicine from Johns Hopkins University, Baltimore. Gwen has extensive industry and academic experience in cellular and gene therapy translational research and development, joining Adaptimmune as a former Director of Translational Research Operations at the University of Pennsylvania and prior to that Director of Scientific Affairs at Virxsys Corporation.